FDA Advisers Recommend Approval of Vanda’s Sleep Drug for the Blind

A A
FDA advisers overwhelmingly voted Nov. 14 to recommend approval of Vanda’s sleep drug tasimelteon for the visually impaired despite some concern over a clinical trial’s primary endpoint.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00